Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2019-06-24 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-06-24 English
SCHEDULE 13G
Major Shareholding Notification
2019-06-19 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date of a Registration Statement on Form F-3. It references a filing (Form F-3) but does not contain financial data or the report itself. The document is short (1342 characters) and is a formal communication related to a regulatory filing process. According to the rules, such a letter is a regulatory announcement related to filings and not the filing itself. Therefore, it should be classified as a Regulatory Filing (RNS).
2019-06-19 English
Regulatory Filings 2019
Regulatory Filings
2019-06-13 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form F-3 Registration Statement filed with the SEC, which is a type of shelf registration statement used by companies to register securities for potential future offerings. It includes details about the securities to be registered, the maximum aggregate offering price, and the terms under which securities may be sold. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing fallback. Hence, the classification is CAP with high confidence.
2019-06-07 English
SCHEDULE 13D
Major Shareholding Notification
2019-05-31 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.